- Home
- ADIL vs SXTP Comparison
ADIL vs SXTP Comparison
Compare ADIL & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- SXTP
- Stock Information
- Founded
- ADIL 2010
- SXTP 2010
- Country
- ADIL United States
- SXTP United States
- Employees
- ADIL N/A
- SXTP N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- SXTP Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- SXTP Health Care
- Exchange
- ADIL Nasdaq
- SXTP Nasdaq
- Market Cap
- ADIL 3.9M
- SXTP 4.3M
- IPO Year
- ADIL 2018
- SXTP 2023
- Fundamental
- Price
- ADIL $0.34
- SXTP $2.32
- Analyst Decision
- ADIL Strong Buy
- SXTP Buy
- Analyst Count
- ADIL 1
- SXTP 2
- Target Price
- ADIL $8.00
- SXTP $7.00
- AVG Volume (30 Days)
- ADIL 22.2M
- SXTP 324.9K
- Earning Date
- ADIL 08-12-2025
- SXTP 08-13-2025
- Dividend Yield
- ADIL N/A
- SXTP N/A
- EPS Growth
- ADIL N/A
- SXTP N/A
- EPS
- ADIL N/A
- SXTP N/A
- Revenue
- ADIL N/A
- SXTP $802,323.00
- Revenue This Year
- ADIL N/A
- SXTP $95.50
- Revenue Next Year
- ADIL N/A
- SXTP $80.78
- P/E Ratio
- ADIL N/A
- SXTP N/A
- Revenue Growth
- ADIL N/A
- SXTP 118.37
- 52 Week Low
- ADIL $0.22
- SXTP $1.41
- 52 Week High
- ADIL $3.00
- SXTP $35.99
- Technical
- Relative Strength Index (RSI)
- ADIL 50.21
- SXTP 50.64
- Support Level
- ADIL $0.22
- SXTP $1.91
- Resistance Level
- ADIL $0.27
- SXTP $2.55
- Average True Range (ATR)
- ADIL 0.08
- SXTP 0.24
- MACD
- ADIL -0.01
- SXTP -0.00
- Stochastic Oscillator
- ADIL 53.15
- SXTP 46.09
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.